Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion

Ophthalmologica

Volumn 226, Issue 2, 2011, Pages 81-86

  Tagami, Mizuki ^a   Kusuhara, Sentaro ^a   Imai, Hisanori ^a   Honda, Shigeru ^a   Tsukahara, Yasutomo ^a   Negi, Akira ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Electroretinogram; Macular oedema; Retinal toxicity; Retinal vein occlusion; Tissue plasminogen activator; Visual acuity

Indexed keywords

MONTEPLASE; MOXIFLOXACIN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ELECTRORETINOGRAM; FEMALE; HUMAN; MALE; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ELECTRORETINOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 79957558017     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000326242     Document Type: Article

References (20)

1. Ip MS, Scott IU, Van Veldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114.
2. Scott IU, Ip MS, Van Veldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128.
3. Campochiaro PA, Heier JS, Feiner L, et al: Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112.
4. Brown DM, Campochiaro PA, Singh RP, et al: Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133.
5. Lahey JM, Fong DS, Kearney J: Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers 1999; 30: 427-434. (Pubitemid 29279445)
6. Glacet-Bernard A, Kuhn D, Vine AK, et al: Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: A pilot study. Br J Ophthalmol 2000; 84: 609-613. (Pubitemid 30339312)
7. Elman MJ, Raden RZ, Carrigan A: Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc 2001; 99: 219-221, discussion 222-223.
8. Murakami T, Takagi H, Kita M, et al: Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006; 142: 318-320. (Pubitemid 44107275)
9. Murakami T, Takagi H, Ohashi H, et al: Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina 2007; 27: 1031-1037. (Pubitemid 350304003)
10. Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN: Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990; 108: 259-263. (Pubitemid 20058162)
11. Hrach CJ, Johnson MW, Hassan AS, et al: Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol 2000; 118: 659-663. (Pubitemid 30327343)
12. Yamamoto T, Kamei M, Kunavisarut P, Suzuki M, Tano Y: Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model. Graefes Arch Clin Exp Ophthalmol 2008; 246: 509-514. (Pubitemid 351447963)
13. Hesse L, Schmidt J, Kroll P: Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999; 237: 273-277. (Pubitemid 29145803)
14. Chen SN, Yang TC, Ho CL, et al: Retinal toxicity of intravitreal tissue plasminogen activator: Case report and literature review. Ophthalmology 2003; 110: 704-708.
15. Marmor MF, Holder GE, Seeliger MW, Yamamoto S: Standard for clinical electroretinography (2004 update). Doc Ophthalmol 2004; 108: 107-114.
16. Wachtmeister L: Oscillatory potentials in the retina: What do they reveal. Prog Retin Eye Res 1998; 17: 485-521. (Pubitemid 28432979)
17. Sakuma T, Mizota A, Inoue J, Tanaka M: Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2010; 150: 876-882.
18. Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd: Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991; 109: 723-729.
19. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98: 271-282.
20. Hayreh SS, Podhajsky PA, Zimmerman MB: Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011; 118: 119-133.